Quantbot Technologies LP Invests $2.22 Million in Insmed, Inc. $INSM

Quantbot Technologies LP purchased a new stake in Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 22,067 shares of the biopharmaceutical company’s stock, valued at approximately $2,221,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hilltop National Bank acquired a new stake in shares of Insmed during the second quarter worth $28,000. ORG Partners LLC grew its stake in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Insmed during the second quarter worth about $33,000. LRI Investments LLC acquired a new stake in Insmed in the 2nd quarter worth about $59,000. Finally, First Horizon Advisors Inc. raised its stake in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 186 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Insmed in a research report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 target price on the stock. Stifel Nicolaus boosted their price target on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Morgan Stanley raised their price objective on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Redburn Partners set a $263.00 price objective on Insmed in a report on Thursday. Finally, Bank of America increased their target price on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $187.89.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $204.00 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The stock has a market capitalization of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The company’s 50 day simple moving average is $180.50 and its 200 day simple moving average is $134.48.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the previous year, the company earned ($1.27) earnings per share. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. As a group, research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $195.90, for a total value of $14,692,500.00. Following the sale, the director directly owned 54,677 shares of the company’s stock, valued at $10,711,224.30. This trade represents a 57.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at approximately $10,089,889.56. This represents a 33.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 233,650 shares of company stock worth $41,063,785 over the last quarter. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.